novartis glp-1 Lilly launches pill, kicking off showdown with Novo Nordisk Novartis inks US$ 5.2 bn

doi: 10.1038/nri2448 24 ZhouJTangZGaoSLiCFengYZhouX

Meanwhile, Eli Lilly, which manufactures Zepbound, is navigating a growing number of legal complaints that accuse the company of not telling people about some of the potential gastrointestinal risks of taking Zepbound

Swallowing a supplement is so 2024

Our team has seen this play out across peptide research contexts repeatedly

These concerns highlight the necessity for ongoing treatment and monitoring during GLP-1 therapy to ensure sustainable weight loss while minimizing adverse outcomes, such as sarcopenia

Interrupting reconstitution to search for supplies risks contamination